Company insight

Innovative platform for drug delivery devices

With SensAIR, Gerresheimer presents a new platform for on-body infusion pumps, which can safely deliver drugs of higher viscosity, such as monoclonal antibodies (mAb) with precise dosing. The aim is to provide patients with the best possible support in the subcutaneous delivery of large- volume biologics.


he ready-to-use SensAIR On-Body Infusor is easy to use and enables patients to start medication in a self-determined manner in familiar surroundings, for example, at home. The SensAIR On-Body Infusor can be adapted to many medications of different viscosities and different requirements. This applies to the size of the medical device as a whole, as well as to the needle used, variable cartridge sizes and possible connectivity, for example to the patient’s smartphone. Together with Gerresheimer’s one-stop-shop quality promise, which includes a solution from the cartridge to the drug delivery device from a single source, SensAIR enables safe and optimised delivery of biologics. “Everyone benefits from SensAIR: patients, their relatives and also doctors. This device is an innovative medical device, which, when worn on the body, delivers up to 20ml of biologics subcutaneously to the patient,” says Oliver Haferbeck, head of the advanced technology and innovation unit at Gerresheimer and CEO of Sensile-Medical. He explains that patients gain significantly in quality of life as they can self-administer their medication at home. The ready-to-use concept ensures that the patient does

not have to carry out any lengthy or complicated preparation steps, but can operate the device simply and safely.

Better quality of life for the patient To date, many patients with a wide variety of indications have to endure long and stressful infusions in a hospital setting to treat their condition. How much easier would it be if patients could carry out the treatment at home? SensAIR makes life easier for these patients, as they can care for themselves over a longer period of time and – depending on the indication – only need to visit the doctor or hospital for check-ups. SensAIR is an innovative product platform for the infusion of large-volume and highly viscous biologics. The technology, function, design and construction of the platform were jointly developed by Gerresheimer specialists and the product is supplied from a single source.

Safety and cost-efficiency The SensAIR Infusor is characterised by a simple and safe concept, which can be cost-effectively adapted to different needs, especially patient needs. Gerresheimer, therefore, offers a platform solution that provides a wide range of options with regard

to the biologic to be applied; starting with the drug flow rate (0.15–1.00ml/min), through type (for example, glass cartridge) and volume (up to 20ml) of the primary packaging, to connectivity. With this focus, SensAIR is attractive to the market even with varying quantities of devices per year, as existing developments and processes can be adapted in the shortest possible time. The existing technologies and know-how, which have already proved themselves in the market, are consistently pursued in SensAIR. This is a significant advantage in terms of time-to-market, among other things, by quickly enabling clinical trials. Gerresheimer is both a partner for the SensAIR device, and a supplier and manufacturer of the primary packaging. This represents significant added value as a long-term partner and system supplier.

An essential role

Gerresheimer is the global partner for pharmaceutics, biotech, healthcare and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging, and drug delivery devices. It is an innovative solution provider from concept to delivery of the end product and achieves its ambitious goals through a high level of innovative strength, industrial competence, and concentration on quality and customer focus.

In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centres in Europe, US and Asia. It produces close to its customers worldwide with around 10,000 employees and generates annual sales of more than €1.4bn. With its products and solutions, Gerresheimer plays an essential role in people’s health and well-being. ●

Gerresheimer presents SensAIR, a new platform for on-body infusion pumps that can safely administer drugs of higher viscosity, such as monoclonal antibodies (mAb) in precise doses.

16 World Pharmaceutical Frontiers /

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53